Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 12/2013

01.12.2013 | Original Paper

Scaling adult dose and schedule of anticancer agents to children

verfasst von: Thomas H. Dawson

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Objective of this work was to extend pharmacokinetic scaling theory of the writer for bolus dosing to include the case of constant-rate i.v. dosing over fixed interval so as to allow projection of adult dose and schedule of typically administered anticancer agents to children.

Methods

The basis for the scaling is the requirement of time-scaled likeness of the plasma concentrations of an agent for adult and child. Algebraic expressions are established for describing the time history of the concentrations, and formulas for dose and dosing interval are determined so as to ensure the requirement on concentrations.

Results

Scaling results for simple drug behavior are illustrated using clinical data for the anticancer agent carboplatin. Basic aspects of the theory are confirmed for dose and dosing interval of adult and 4-year-old child. The theory is also shown to describe tolerable doses for children when scaled from adult dosing requirements and to have application in determining dosing conditions for children requiring individualized dosing because of renal impairment. Scaling with more complex drug behavior is illustrated using preclinical and clinical data for the anticancer agent docetaxel. Adult-to-child scaling is demonstrated and shown to be consistent with previously reported clinical data. Additional consideration is given to the anticancer agents etoposide and melphalan, as widely used in pediatric chemotherapy, and also to the modern practice of combination chemotherapy.

Conclusions

Basic theory for scaling adult dose and schedule of anticancer agents to children is presented and demonstrated to be plausible in providing insight into existing and proposed pediatric treatment protocols.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Blaney SM, Seibel NL, O’Brien M, Reaman GH, Berg SL, Adamson PC, Poplack DG, Krailo MD, Mosher R, Balis F (1997) Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children’s Cancer Group Trial. J Clin Oncol 15:1538–1543PubMed Blaney SM, Seibel NL, O’Brien M, Reaman GH, Berg SL, Adamson PC, Poplack DG, Krailo MD, Mosher R, Balis F (1997) Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children’s Cancer Group Trial. J Clin Oncol 15:1538–1543PubMed
Zurück zum Zitat Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756PubMed Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756PubMed
Zurück zum Zitat Clarke SJ, Rivory LP (1996) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99–114CrossRef Clarke SJ, Rivory LP (1996) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99–114CrossRef
Zurück zum Zitat Clerico A, Cappelli C, Ragni G, Caroli S, DeIoris MA, Sordi A, Petrucci F, Bocca B, Alimonti A (2006) Evaluation of carboplatin pharmacokinetics in pediatric oncology by means of inductively coupled plasma mass spectrometry. Ann Ist Super Sanita 42(4):461–468PubMed Clerico A, Cappelli C, Ragni G, Caroli S, DeIoris MA, Sordi A, Petrucci F, Bocca B, Alimonti A (2006) Evaluation of carboplatin pharmacokinetics in pediatric oncology by means of inductively coupled plasma mass spectrometry. Ann Ist Super Sanita 42(4):461–468PubMed
Zurück zum Zitat Dawson TH (1991) Engineering design of the cardiovascular system of mammals. Prentice Hall, Englewood Cliffs Dawson TH (1991) Engineering design of the cardiovascular system of mammals. Prentice Hall, Englewood Cliffs
Zurück zum Zitat Dawson TH (2001) Similitude in the cardiovascular system of mammals. J Exp Biol 204:395–407PubMed Dawson TH (2001) Similitude in the cardiovascular system of mammals. J Exp Biol 204:395–407PubMed
Zurück zum Zitat Dawson TH (2008) Modeling the vascular system and its capillary networks. In: Yim PJ (ed) Vascular hemodynamics. Wiley–Blackwell, Hoboken, pp 1–35 Dawson TH (2008) Modeling the vascular system and its capillary networks. In: Yim PJ (ed) Vascular hemodynamics. Wiley–Blackwell, Hoboken, pp 1–35
Zurück zum Zitat Dawson TH (2010) Scaling laws for plasma concentrations and tolerable doses of anticancer drugs. Cancer Res 70:4801–4808CrossRefPubMed Dawson TH (2010) Scaling laws for plasma concentrations and tolerable doses of anticancer drugs. Cancer Res 70:4801–4808CrossRefPubMed
Zurück zum Zitat Ettinger LJ, Kralio MD, Gaynon PS, Hammond GD (1993) A phase I study of carboplatin in children with acute leukemia in bone marrow relapse. A report from the Childrens Cancer Group. Cancer 1993(72):917–922CrossRef Ettinger LJ, Kralio MD, Gaynon PS, Hammond GD (1993) A phase I study of carboplatin in children with acute leukemia in bone marrow relapse. A report from the Childrens Cancer Group. Cancer 1993(72):917–922CrossRef
Zurück zum Zitat Mahmood I (2006) Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 61:545–557PubMedCentralCrossRefPubMed Mahmood I (2006) Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 61:545–557PubMedCentralCrossRefPubMed
Zurück zum Zitat Martinez JA, Martin G, Sanz GF, Sempere A, Jarque I, de la Rubia J, Sanz MA (1991) A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J Clin Oncol 9:39–43PubMed Martinez JA, Martin G, Sanz GF, Sempere A, Jarque I, de la Rubia J, Sanz MA (1991) A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J Clin Oncol 9:39–43PubMed
Zurück zum Zitat Nath CE, Shaw PJ, Montgomery K, Earl JW (2004) Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total-body irradiation. Br J Clin Pharmacol 59(3):314–324CrossRef Nath CE, Shaw PJ, Montgomery K, Earl JW (2004) Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total-body irradiation. Br J Clin Pharmacol 59(3):314–324CrossRef
Zurück zum Zitat Nath CE, Shaw PJ, Montgomery K, Earl JW (2007) Population pharmacokinetics of melphalan in paediatric blood of marrow transplant recipients. Br J Clin Pharmacol 64(2):151–164PubMedCentralCrossRefPubMed Nath CE, Shaw PJ, Montgomery K, Earl JW (2007) Population pharmacokinetics of melphalan in paediatric blood of marrow transplant recipients. Br J Clin Pharmacol 64(2):151–164PubMedCentralCrossRefPubMed
Zurück zum Zitat Newell DR, Pearson ADJ, Balmanno K, Price L, Wyllie RA, Keir M, Calvert AH, Lewis IJ, Pinkerton CR, Stevens MC (1993) Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 11:2314–2323PubMed Newell DR, Pearson ADJ, Balmanno K, Price L, Wyllie RA, Keir M, Calvert AH, Lewis IJ, Pinkerton CR, Stevens MC (1993) Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 11:2314–2323PubMed
Zurück zum Zitat Salminen E, Bergman M, Huhtala S, Ekholm E (1999) Docetaxel: Standard recommended dose of 100 mg/m2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy—a phase II single-center study. J Clin Oncol 17:1127–1131PubMed Salminen E, Bergman M, Huhtala S, Ekholm E (1999) Docetaxel: Standard recommended dose of 100 mg/m2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy—a phase II single-center study. J Clin Oncol 17:1127–1131PubMed
Zurück zum Zitat Schwartz JG, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832–1843CrossRefPubMed Schwartz JG, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832–1843CrossRefPubMed
Zurück zum Zitat Seckel H (1936) Blood volume and circulation time in children. Arch Dis Child 11:21–30CrossRef Seckel H (1936) Blood volume and circulation time in children. Arch Dis Child 11:21–30CrossRef
Zurück zum Zitat Sinkule JA, Hutson P, Hayes FA, Etcubanas E, Evans W (1984) Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer Res 44:3109–3113PubMed Sinkule JA, Hutson P, Hayes FA, Etcubanas E, Evans W (1984) Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer Res 44:3109–3113PubMed
Metadaten
Titel
Scaling adult dose and schedule of anticancer agents to children
verfasst von
Thomas H. Dawson
Publikationsdatum
01.12.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-013-1508-z

Weitere Artikel der Ausgabe 12/2013

Journal of Cancer Research and Clinical Oncology 12/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.